SEC Form 4 · accession 0001209191-18-062336
ANAPTYSBIO, INC · ANAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hamza Suria
Officer — President, CEO · Director
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 8:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001370053
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 10, 2018 | M | 30,587 | $1.12 | A | 65,649 | D | |
| Common StockF2 | Dec 10, 2018 | S | 15,276 | $70.5736 | D | 50,373 | D | |
| Common StockF3 | Dec 10, 2018 | S | 10,347 | $71.4894 | D | 40,026 | D | |
| Common StockF4 | Dec 10, 2018 | S | 4,964 | $72.4829 | D | 35,062 | D | |
| Common Stock | Dec 11, 2018 | S | 4,998 | $70.83 | D | 30,064 | D | |
| Common Stock | Dec 12, 2018 | M | 30,000 | $1.12 | A | 60,064 | D | |
| Common StockF5 | Dec 12, 2018 | S | 12,003 | $71.1056 | D | 48,061 | D | |
| Common StockF6 | Dec 12, 2018 | S | 9,673 | $71.9237 | D | 38,388 | D | |
| Common StockF7 | Dec 12, 2018 | S | 8,324 | $72.8758 | D | 30,064 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F8 | $1.12 | Dec 10, 2018 | M | 30,587 | D | — | Dec 8, 2021 | Common Stock | 30,587 | 110,361 | D |
| Employee Stock OptionF9,F8 | $1.12 | Dec 12, 2018 | M | 30,000 | D | — | Dec 8, 2021 | Common Stock | 30,000 | 80,361 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.01 to $71.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.01 to $71.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.13 to $73.07 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.51 to $71.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.51 to $72.48 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.52 to $73.04 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8The stock option is fully vested and immediately exercisable.
- F9In addition to the remaining options to purchase 80,361 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 796,205 shares of common stock, which options vest according to their terms, and (ii) 30,064 shares of common stock held directly.
Remarks
Exhibit List - Exhibit 24.1 - Power of Attorney